Why it matters
AI is becoming embedded across regulated product development rather than remaining a separate digital-health category.
Decision implication
Track where FDA expectations become more explicit by phase and build those requirements into evidence/adoption readiness for AI-enabled life-science products.
Who or what is affected
- FDA CDER
- biopharma
- AI developers
- clinical-research organizations
Evidence and sources
Decision priority: Watch
Source authority: Primary/authoritative · official FDA source
Evidence design: Program record
Applicability: Direct
Confidence for the stated claim: High
Freshness: Current
P4L distinguishes the sourced record from interpretation. Program inclusion, participation, funding, proposal status, or a public listing does not by itself establish clinical effectiveness, endorsement, coverage, or scaled adoption unless the cited source specifically establishes it.
For this decision
Clinicians · Innovators · Health-system leaders · Policymakers
What P4L is watching next
- Guidance
- submission examples
- validation expectations
- postmarket use.
Related proof records
Record provenance
- Last verified
- 2026-09-03
- Source updated
- 2026-05-01
- Revision state
- Version 1.1 records the September 3, 2026 re-verification and clarifies that FDA describes a submission trend, not approvals or endorsement.
- Status
- Current FDA regulatory-trend statement · not endorsement
- Freshness
- Current
- Version
- 1.1
- Stable ID
- SIG-2026-021